Share：
Share this content in WeChat
X
[Chinese][PDF]98984
• Review •
Research progress of background parenchymal enhancement in breast magnetic resonance imaging
ZHANG Rong  YANG Xiaoping 

Cite this article as: Zhang R, Yang XP. Research progress of background parenchymal enhancement in breast magnetic resonance imaging[J]. Chin J Magn Reson Imaging, 2021, 12(3): 102-104, 108. DOI:10.12015/issn.1674-8034.2021.03.025.


[Abstract] Breast cancer is the most common malignant tumor in women, which has high morbidity and mortality rates, and different molecular subtypes of breast cancer have different biological manifestations and clinical treatment prognosis. Therefore, the search for targeted and personalized imaging markers for diagnosis and treatment of breast cancer is a hot of current research. Background parenchymal enhancement (BPE) on breast magnetic resonance imaging (MRI) is an increasingly studied parameter that reflects the microvasculature of normal breast tissue, is influenced by many factors, and in the diagnosis and treatment prognosis of mammary gland disease has important diagnostic value. BPE has profound implications for women with or at risk of breast cancer, and may assess the curative effect of neoadjuvant chemotherapy of breast cancer. BPE shows promise as an imaging biomarker but many issues need to be addressed before it can be used either to determine screening strategy or the value of risk-reducing interventions. This review analyzes the influence factors of BPE and role in the diagnosis and treatment of breast cancer screening evaluation.
[Keywords] breast cancer；magnetic resonance imaging；background parenchymal enhancement；neoadjuvant chemotherapy；dynamic contrast-enhanced magnetic resonance imaging

ZHANG Rong1   YANG Xiaoping1, 2*  

1 The Second Clinical Medical College of Lanzhou University, Lanzhou 730030, China

2 Department of Radiology, Taizhou Central Hospital, Taizhou 318300, China

Yang XP, E-mail: lwyxp_zxl@sohu.com

Conflicts of interest   None.

ACKNOWLEDGMENTS  This article is supported by Zhejiang Medical and Health Science and Technology Project No. 2020KY1050
Received  2020-11-04
Accepted  2021-01-21
DOI: 10.12015/issn.1674-8034.2021.03.025
Cite this article as: Zhang R, Yang XP. Research progress of background parenchymal enhancement in breast magnetic resonance imaging[J]. Chin J Magn Reson Imaging, 2021, 12(3): 102-104, 108. DOI:10.12015/issn.1674-8034.2021.03.025.

1
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin, 2020, 70(1): 7-30. DOI: 10.3322/caac.21590
2
Zheng RS, Sun KX, Zhang SW, et.al..Report of cancer epidemiology in China. Chin J Oncol, 2019, 41(1): 19-28.
3
Leithner D, Helbich TH, Bernard-Davila B, et al. Multiparametric 18F-FDG PET/MRI of the Breast: are there differences in imaging biomarkers of contralateral healthy tissue between patients with and without breast cancer?. J Nucl Med, 2020, 61(1): 20-25. DOI: 10.2967/jnumed.119.230003
4
Mann RM, Pinker K. Is background parenchymal enhancement an important risk factor for breast cancer development in women with increased risk?Radiology, 2019, 292(3): 562-563. DOI: 10.1148/radiol.2019191164
5
Thompson CM, Mallawaarachchi I, Dwivedi DK, et al. The association of background parenchymal enhancement at breast MRI with breast cancer: a systematic review and Meta-analysis. Radiology, 2019, 292(3): 552-561. DOI: 10.1148/radiol.2019182441
6
Morris EA, Comstock CE, Lee CH, et al. ACR BIRADS® magnetic resonance Imaging. ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. Reston: American College of Radiology, 2013.
7
Giess CS, Yeh ED, Raza S, et al. Background parenchymal enhancement at breast MR imaging: normal patterns, diagnostic challenges, and potential for falsepositive and false-negative interpretation. RadiogGraphics, 2014, 34(1): 234-247. DOI: 10.1148/rg.341135034
8
Heller SL, Young Lin LL, Melsaether AN, et al. Hormonal effects on breast density, fibroglandular tissue, and back-ground parenchymal enhancement. Radiographics, 2018, 38(4): 983-996. DOI: 10.1148/rg.2018180035
9
Liao GJ, Henze Bancroft LC, Strigel RM, et al. Background parenchymal enhancement on breast MRI: a comprehensive review. J Magn Reson Imaging, 2020, 51(1): 43-61. DOI: 10.1002/jmri.26762
10
O'Flynn EA, Morgan VA, Giles SL, et al. Diffusion weighted imaging of the normal breast: reproducibility of apparent diffusion coefficient measurements and variation with menstrual cycle and menopausal status. Eur Radiol, 2012, 22(7): 1512-1518. DOI: 10.1007/s00330-012-2399-0
11
Partridge SC, Mckinnon GC, Henry RG, et al. Menstrual cycle variation of apparent diffusion coefficients measured in the normal breast using MRI. J Magn Reson Imaging, 2010, 14(4): 433-438. DOI: 10.1002/jmri.1204
12
Jung Y, Jeong SK, Kang DK, et al. Quantitative analysis of background parenchymal enhancement in whole breast on MRI: Influence of menstrual cycle and comparison with a qualitative analysis. Eur Radiol, 2018, 103(2018): 84-89. DOI: 10.1016/j.ejrad.2018.04.009
13
Jung Y, Jeong S, Kim JY, et al. Correlations of female hormone levels with background parenchymal enhancement and apparent diffusion coefficient values in premenopausal breast cancer patients: effects on cancer visibility. Eur Radiol, 2020, 124(2020): 108818. DOI: 10.1016/j.ejrad.2020.108818
14
Lee CH, Bryce Y, Zheng J, et al. Outcome of screening mri in premenopausal women as a function of the week of the menstrual cycle. AJR Am J Roentgenol, 2020, 214(5): 1175-1181. DOI: 10.2214/AJR.18.19960
15
Dontchos BN, Habib R, Partridge SC, et al. Influence of menstrual cycle timing on screening breast MRI background parenchymal enhancement and diagnostic performance in premenopausal women. J Breast Imaging, 2019, 1(3): 205-211. DOI: 10.1093/jbi/wbz022
16
Kuhl CK, Bieling HB, Gieseke J, et al. Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology, 1997, 203(1): 137-144.
17
King V, Gu Y, Kaplan JB, et al. Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI. Eur Radiol, 2012, 22(12): 2641-2647. DOI: 10.1007/s00330-012-2553-8
18
Hizan NS, Hasnina H, Hassan M, et al. Tualang honey adjunct with anastrozole improve parenchyma enhancement of breast tissue in breast cancer patients: a randomized controlled trial. Integr Med Res, 2018, 7(4): 322-327. DOI: 10.1016/j.imr.2018.07.002
19
Kuhl C. The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. Radiology, 2007, 244(2): 356-378. DOI: 10.1148/radiol.2442051620
20
Hellgren R, Saracco A, Strand F, et al. The association between breast cancer risk factors and background parenchymal enhancement at dynamic contrast-enhanced breast MRI. Acta Radiol, 2020. DOI: . DOI: 10.1177/0284185120911583
21
Dontchos BN, Rahbar H, Partridge SC, et al. Are qualitative assessments of background parenchymal enhancement, amount of fibroglandular tissue on mr images, and mammographic density associated with breast cancer risk?Radiology, 2015, 276(2): 371-380. DOI: 10.1148/radiol.2015142304
22
Arasu VA, Miglioretti DL, Sprague BL, et al. Population-based assessment of the association between magnetic resonance imaging background parenchymal enhancement and future primary breast cancer risk. J Clin Oncol, 2019, 37(12): 954-963. DOI: 10.1200/JCO.18.00378
23
Demartini WB, Liu F, Peacock S, et al. Background parenchymal enhancement on breast MRI: impact on diagnostic performance. AJR Am. J. Roentgenol, 2012, 198(4): 373-380. DOI: 10.2214/AJR.10.6272
24
Derks MGM, van de Velde CJH. Neoadjuvant chemotherapy in breast cancer: more than just downsizing. Lancet Oncol, 2018, 19(1): 2-3. DOI: 10.1016/S1470-2045(17)30914-2
25
Teixeira SRC, de Camargo Júnior HSA, Cabello C. Background parenchymal enhancement: behavior during neoadjuvant chemotherapy for breast cancer and relationship with a pathological complete response. Radiol Bras, 2020, 53(2): 95-104. DOI: 10.1590/0100-3984.2019.0057
26
Moliere S, Oddou I, Noblet V, et al. Quantitative background parenchymal enhancement to predict recurrence after neoadjuvant chemotherapy for breast cancer. Scientific Reports, 2019, 9(1): 19185. DOI: 10.1038/s41598-019-55820-5
27
Dong JM, Wang HX, Zhong XF, et al. Changes in background parenchymal enhancement in HER2-positive breast cancer before and after neoadjuvant chemotherapy: association with pathologic complete response. Medicine, 2018, 97(43): e12965. DOI: 10.1097/MD.0000000000012965
28
Talal H, Matthew C, Kosiorek HE, et al. Breast MRI phenotype and background parenchymal enhancement may predict tumor response to neoadjuvant endocrine therapy. Breast J, 2018, 24(6): 1010-1014. DOI: 10.1111/tbj.13101
29
Wu SD2, Weinstein SP, DeLeo MJ 3rd, et, al. Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers. Breast Cancer Research Bcr, 2015, 17(1): 144. DOI: 10.1186/s13058-015-0577-0
30
Sippo DA, Rutledge GM, Mercaldo SF, et al. Impact of background parenchymal enhancement on diagnostic performance in screening breast MRI. Acad Radiol, 2020, 27(5): 663-671. DOI: 10.1016/j.acra.2019.06.020
31
Hambly NM, Liberman L, Dershaw DD, et al. Background parenchymal enhancement on baseline screening breast MRI: impact on biopsy rate and short-interval follow-up. AJR Am J Roentgenol, 2011, 196(1): 218-224. DOI: 10.2214/AJR.10.4550/
32
Melsaether A, Pujara AC, Elias K, et al. Background parenchymal enhancement over exam time in patients with and without breast cancer. J Magn Reson Imaging, 2017, 45(1): 74-83. DOI: 10.1002/jmri.25338
33
Shin GW, Zhang Y, Kim MJ, et al. Role of dynamic contrast-enhanced MRI in evaluating the association between contralateral parenchymal enhancement and survival outcome in ER-positive, HER2-negative, node-negative invasive breast cancer. J Magn Reson Imaging, 2018, 48(6): 1678-1689. DOI: 10.1002/jmri.26176
34
Kim SA, Cho N, Ryu EB, et al. Background parenchymal signal enhancement ratio at preoperative MR imaging: Association with subsequent local recurrence in patients with ductal carcinoma in situ after breast conservation surgery. Radiology, 2014, 270(3): 699-707. DOI: 10.1148/radiol.13130459
35
Kim MY, Cho N, Koo HR, et al. Predicting local recurrence following breast-conserving treatment: parenchymal signal enhancement ratio(SER) around the tumor on preoperative MRI. Acta Radiol, 2013, 54(7): 731-738. DOI: 10.1177/0284185113483676
36
Park VY, Kim EK, Kim MJ, et al. Breast parenchymal signal enhancement ratio at preoperative magnetic resonance imaging: association with early recurrence in triple-negative breast cancer patients. Acta Radiol, 2016, 57(7): 802-808. DOI: 10.1177/0284185115609803
37
Jung Y, Jeong SK, Kang DK, et al. Quantitative analysis of background parenchymal enhancement in whole breast on MRI: influence of menstrual cycle and comparison with a qualitative analysis. Eur J Radiol, 2018,103(2018): 84-89. DOI: 10.1016/j.ejrad.2018.04.009/
38
Zhang Y, Chen JH, Chang KT, et al. Automatic breast and fibroglandular tissue segmentation in breast MRI using deep learning by a fully-convolutional residual neural network U-Net. Acad Radiol, 2019, 26(11): 1526-1535. DOI: 10.1016/j.acra.2019.01.012

PREV Application of cardiac magnetic resonance extracellular volume in hypertensive heart disease
NEXT Application progress of MRI-based artificial intelligence in the diagnosis of liver fibrosis
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn